News

Tuesday, 24. September 2024 | Filed under Company News

Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs

Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.

Read more…

Tuesday, 17. September 2024 | Filed under Company News

ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base

— Existing investors and new investor Double Point Ventures join forces to support ImmunOs Therapeutics

— Investment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers

ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.

Read more…

Wednesday, 24. July 2024 | Filed under Company News

ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors

— Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA®

ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, today announced the expansion of its ongoing  Phase I clinical trial of IOS-1002 in combination with MSD (Merck & Co., Inc., Rahway, NJ, USA)’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced solid tumors.

Read more…